SCHEMBL24476407

SCHEMBL24476407

C#C[C@]1(O)CCC2C3C(CC[C@@]21C)C1C=CC(=O)C=C1C[C@H]3C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 6/20 0.53
▸ CYP2C19 P33261 4/20 0.53
▸ ESR1 P03372 4/20 0.53
▸ NR3C1 P04150 3/20 0.53
▸ SLC6A4 P31645 3/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ OPRK1 P41145 2/20 0.53
▸ ADORA3 P0DMS8 2/20 0.53
▸ PTGS2 P35354 1/20 0.53
▸ SLC6A3 Q01959 1/20 0.53
▸ PDE4D Q08499 1/20 0.53
▸ SHBG P04278 6/20 0.49
▸ LMNA P02545 4/20 0.49
▸ CYP3A4 P08684 4/20 0.49
▸ ABCB11 O95342 3/20 0.49
▸ HIF1A Q16665 3/20 0.49
▸ TSHR P16473 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ ADRA2A P08913 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24476668 0.84 CYP3A4 (0.66) PGRCYP2C19ESR1NR3C1SLC6A4
SCHEMBL6873042 0.81 PGR (0.72) PGRCYP2C19ESR1NR3C1SLC6A4
SCHEMBL2835215 0.81 PGR (0.72) PGRCYP2C19ESR1NR3C1SLC6A4
SCHEMBL23805202 0.81 PGR (0.72) PGRCYP2C19ESR1NR3C1SLC6A4
SCHEMBL6245967 0.81 PGR (0.72) PGRCYP2C19ESR1NR3C1SLC6A4
SCHEMBL23822244 0.77 PGR (0.54) PGRCYP2C19ESR1NR3C1SLC6A4
SCHEMBL24476271 0.77 PGR (0.54) PGRCYP2C19ESR1NR3C1SLC6A4
SCHEMBL24476431 0.77 PGR (0.54) PGRCYP2C19ESR1NR3C1SLC6A4
SCHEMBL24476268 0.77 PGR (0.54) PGRCYP2C19ESR1NR3C1SLC6A4
SCHEMBL5974963 0.77 PGR (0.54) PGRCYP2C19ESR1NR3C1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169672-A1 COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER PURDUE RESEARCH FOUNDATION 2022-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169672-A1 COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER KLK3, AR, ACP3 PGR 777/4885CYP2C19 3711/4885ESR1 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback